Ovarian Neoplasms  >>  Perjeta (pertuzumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Perjeta (pertuzumab) / Roche
PENELOPE, NCT01684878 / 2011-005975-17: Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer

Checkmark Platinum-Resistant Ovarian Cancer
Jun 2016 - Jun 2016: Platinum-Resistant Ovarian Cancer
Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark P2 data
More
Completed
3
208
Europe
Gemcitabine (Chemotherapy), Paclitaxel (Chemotherapy), Pertuzumab, Placebo, Topotecan (Chemotherapy)
Hoffmann-La Roche
Ovarian Cancer
01/15
04/16

Download Options